•
Jun 30, 2024

Teva Q2 2024 Earnings Report

Teva reported strong revenue growth driven by generics and AUSTEDO, and raised its 2024 financial guidance.

Key Takeaways

Teva's Q2 2024 revenues reached $4.2 billion, a 7% increase in U.S. dollars or 11% in local currency, driven by generics and innovative businesses. AUSTEDO grew 32% in the U.S. The company is raising its financial guidance for 2024.

Global revenues increased by 7% to $4.2 billion, or 11% in local currency.

AUSTEDO revenues in the U.S. increased by 32%.

Non-GAAP diluted earnings per share increased to $0.61, compared to $0.56 in the second quarter of 2023.

The company raised its financial guidance for 2024.

Total Revenue
$4.16B
Previous year: $3.88B
+7.4%
EPS
$0.61
Previous year: $0.56
+8.9%
Gross Profit
$2.02B
Previous year: $1.8B
+12.7%
Cash and Equivalents
$2.26B
Previous year: $2.67B
-15.4%
Free Cash Flow
$324M
Previous year: $632M
-48.7%
Total Assets
$41.3B
Previous year: $43.1B
-4.1%

Teva

Teva

Teva Revenue by Segment

Teva Revenue by Geographic Location

Forward Guidance

Teva is raising its financial guidance for 2024.

Revenue & Expenses

Visualization of income flow from segment revenue to net income